Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM103-Next
- Development stage
- Preclinical
- Lead developer
- Suzhou Lanma Medical Technology
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
LM103-Next is a next-generation tumor-infiltrating lymphocyte (TIL) therapy developed by Suzhou Lanma Medical Technology Co. Ltd. (also known as Suzhou BlueHorse). It represents an optimized manufacturing iteration of the company's lead TIL candidate, LM103, designed to enhance the quality, potency, and production efficiency of autologous lymphocytes harvested from solid tumors. The therapy involves the ex vivo expansion of tumor-resident T cells, which are then re-infused into the patient to recognize and eliminate cancer cells. LM103-Next is currently in the IND-enabling and investigator-initiated trial (IIT) stages for the treatment of various advanced solid tumors.
- Other names
- LM103 NextLM-103 NextLM 103 Next
Beyond the preview
Go deeper on LM103-Next.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LM103-Next.